Literature DB >> 27730455

Update on quality of life in patients with acromegaly.

Iris Crespo1, Elena Valassi1, Susan M Webb2.   

Abstract

In recent years, health-related quality of life (QoL) has been considered an important outcome for clinical management of acromegaly. Poor QoL has been described in acromegalic patients with active disease as well as after endocrine cure. It is known that acromegaly determines many physical problems and psychological dysfunctions that unavoidably impact on patients' QoL. Moreover, there is evidence that factors, such as radiotherapy or post-treatment GH deficiency also impair QoL in patients diagnosed with acromegaly. Thus, including the assessment of QoL in daily clinical practice has become fundamental to understand the consequences of acromegaly and the impact on the patients' daily life.

Entities:  

Keywords:  Acromegaly; Quality of life; Quality of life questionnaires; Self-perception; Wellbeing

Mesh:

Year:  2017        PMID: 27730455     DOI: 10.1007/s11102-016-0761-y

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  30 in total

Review 1.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

2.  Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly.

Authors:  Jitske Tiemensma; Adrian A Kaptein; Alberto M Pereira; Johannes W A Smit; Johannes A Romijn; Nienke R Biermasz
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

3.  Clinical characteristics of pain in patients with pituitary adenomas.

Authors:  C Dimopoulou; A P Athanasoulia; E Hanisch; S Held; T Sprenger; T R Toelle; J Roemmler-Zehrer; J Schopohl; G K Stalla; C Sievers
Journal:  Eur J Endocrinol       Date:  2014-08-12       Impact factor: 6.664

4.  The Nottingham Health Profile: subjective health status and medical consultations.

Authors:  S M Hunt; S P McKenna; J McEwen; J Williams; E Papp
Journal:  Soc Sci Med A       Date:  1981-05

5.  Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly.

Authors:  Mark R Postma; Romana T Netea-Maier; Gerrit van den Berg; Jens Homan; Wim J Sluiter; Margreet A Wagenmakers; Alfons C M van den Bergh; Bruce H R Wolffenbuttel; Ad R M M Hermus; André P van Beek
Journal:  Eur J Endocrinol       Date:  2012-01-16       Impact factor: 6.664

6.  Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.

Authors:  Maria P Matta; Elisabeth Couture; Laurent Cazals; Delphine Vezzosi; Antoine Bennet; Philippe Caron
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

7.  Quality of life in patients with a pituitary adenoma.

Authors:  Michelle D Johnson; C J Woodburn; Mary Lee Vance
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

8.  Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.

Authors:  S J C M M Neggers; M O van Aken; W W de Herder; R A Feelders; J A M J L Janssen; X Badia; S M Webb; A J van der Lely
Journal:  J Clin Endocrinol Metab       Date:  2008-07-22       Impact factor: 5.958

9.  Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly.

Authors:  Agatha A van der Klaauw; Nienke R Biermasz; Hendrieke C Hoftijzer; Alberto M Pereira; Johannes A Romijn
Journal:  Clin Endocrinol (Oxf)       Date:  2008-07-01       Impact factor: 3.478

10.  Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life.

Authors:  Victor Jacobus Geraedts; Christina Dimopoulou; Matthias Auer; Jochen Schopohl; Günter Karl Stalla; Caroline Sievers
Journal:  Front Endocrinol (Lausanne)       Date:  2015-01-06       Impact factor: 5.555

View more
  10 in total

1.  AcroVoice: the controversial values in reflecting acromegaly disease activity.

Authors:  Zihao Wang; Bing Xing
Journal:  Pituitary       Date:  2019-08       Impact factor: 4.107

2.  Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.

Authors:  Roberto Salvatori; Pietro Maffei; Susan M Webb; Thierry Brue; Jane Loftus; Srinivas Rao Valluri; Roy Gomez; Michael P Wajnrajch; Maria Fleseriu
Journal:  Pituitary       Date:  2022-01-12       Impact factor: 4.107

3.  Stigma and unhealthy psychological characteristics in patients with acromegaly: A cross-sectional study and identification of the associated factors.

Authors:  Yanqing Li; Xiaomei Zhang; Jiajia Zhang; Dandan Zhang; Ya Wang; Yingqian Zhu; Xiuqun Xu
Journal:  Acta Neurochir (Wien)       Date:  2022-05-21       Impact factor: 2.816

Review 4.  Acromegaly and Colorectal Neoplasm: An Update.

Authors:  Leandro Kasuki; Bernardo Maia; Mônica R Gadelha
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

5.  Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response.

Authors:  Joan Gil; Montserrat Marques-Pamies; Elena Valassi; Araceli García-Martínez; Guillermo Serra; Cristina Hostalot; Carmen Fajardo-Montañana; Cristina Carrato; Ignacio Bernabeu; Mónica Marazuela; Helena Rodríguez-Lloveras; Rosa Cámara; Isabel Salinas; Cristina Lamas; Betina Biagetti; Andreu Simó-Servat; Susan M Webb; Antonio Picó; Mireia Jordà; Manel Puig-Domingo
Journal:  Biomedicines       Date:  2022-02-16

6.  Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly.

Authors:  Ignacio Bernabéu; Carmen Fajardo; Mónica Marazuela; Fernando Cordido; Eva María Venegas; Pedro de Pablos-Velasco; Gonzalo Piedrola Maroto; María Pilar Olvera; Isabel Pavón de Paz; Davide Carvalho; Carme Romero; Guillermo De la Cruz; Cristina Álvarez Escolá
Journal:  Endocrine       Date:  2020-07-28       Impact factor: 3.633

7.  Health-related Quality of Life in Acromegaly Patients: Results from Generic and Disease-specific Questionnaires.

Authors:  Bruno de A Oliveira; Bruna Araújo; Tainá M Dos Santos; Bárbara R Ongaratti; Carolina G S Leães Rech; Nelson P Ferreira; Júlia F S Pereira-Lima; Miriam da C Oliveira
Journal:  Indian J Endocrinol Metab       Date:  2020-11-09

8.  Differences in quality of life between genders in acromegaly.

Authors:  Daniel Ballesteros-Herrera; Paulina Briseño-Hernández; Rodrigo Pérez-Esparza; Lesly A Portocarrero-Ortiz
Journal:  Endocrinol Diabetes Metab       Date:  2021-02-03

9.  Predictors of improvement in quality of life at 12-month follow-up in patients undergoing anterior endoscopic skull base surgery.

Authors:  Quinlan D Buchlak; Nazanin Esmaili; Christine Bennett; Yi Yuen Wang; James King; Tony Goldschlager
Journal:  PLoS One       Date:  2022-07-27       Impact factor: 3.752

10.  Development of a visual tool to assess six dimensions of health and its validation in patients with endocrine disorders.

Authors:  Christian Fazekas; Dennis Linder; Franziska Matzer; Christian Vajda; Alexander Avian; Verena Theiler-Schwetz; Christian Trummer; Julia Došen; Jelena Rokvic; Marco Mohl; Stefan Pilz
Journal:  Wien Klin Wochenschr       Date:  2021-02-04       Impact factor: 2.275

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.